ME Therapeutics Holdings Inc. (CSE:METX)

Market Cap	88.65M -20.5%
Revenue (ttm)	n/a
Net Income	-1.34M
EPS	-0.04
Shares Out	30.05M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	650
Open	2.950
Previous Close	2.950
Day's Range	2.950 - 2.950
52-Week Range	2.000 - 10.400
Beta	0.12
RSI	47.31
Earnings Date	May 12, 2026

About ME Therapeutics Holdings

ME Therapeutics Holdings Inc., a preclinical stage biotechnology company, engages in the development of cancer fighting drugs in the field of immuno-oncology. The company’s lead candidate, h1B11-12, is a glycoprotein cytokine antibody drug that targets a key protein involved in the generation of suppressive myeloid cells for the treatment of colorectal cancer. It also develops D094 and D099, which are small molecule myeloid targeted prodrug candidates to treat cancer; and myeloid targeting lipid nanoparticles (LNPS) formulations. ME Therapeutic...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Country: Canada
• Stock Exchange: Canadian Securities Exchange
• Ticker Symbol: METX